InsiderTrades.com logo
Patrick Lamy net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Patrick Lamy Biography and Net Worth

SVP of Commercial Strategy of Akero Therapeutics

Patrick Lamy is Senior Vice President of Commercial Strategy at Akero. He brings over 25 years of experience in building commercial teams, leading global product launches, and developing strategic plans to ensure the success of both large and small pharmaceutical companies. Prior to joining Akero, he held various commercial planning and strategy, and alliance management roles at Iovance Biotherapeutics and Gilead Sciences. Patrick studied biochemistry and cellular biology at the University of California, San Diego, and received his M.B.A. from the University of California Berkeley.

What is Patrick Lamy's net worth?

The estimated net worth of Patrick Lamy is at least $1.52 million as of March 3rd, 2025. Mr. Lamy owns 33,492 shares of Akero Therapeutics stock worth more than $1,515,178 as of March 26th. This net worth evaluation does not reflect any other investments that Mr. Lamy may own. Learn More about Patrick Lamy's net worth.

How old is Patrick Lamy?

Mr. Lamy is currently 51 years old. There are 6 older executives and no younger executives at Akero Therapeutics. The oldest executive at Akero Therapeutics is Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer, who is 70 years old. Learn More on Patrick Lamy's age.

How do I contact Patrick Lamy?

The corporate mailing address for Mr. Lamy and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at akero@sternir.com. Learn More on Patrick Lamy's contact information.

Has Patrick Lamy been buying or selling shares of Akero Therapeutics?

Over the course of the past ninety days, Patrick Lamy has sold $333,240.00 in shares of Akero Therapeutics stock. Most recently, Patrick Lamy sold 1,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $48.09, for a transaction totalling $48,090.00. Following the completion of the sale, the vice president now directly owns 33,492 shares of the company's stock, valued at $1,610,630.28. Learn More on Patrick Lamy's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $9,600,000.00. During the last twelve months, insiders at the sold shares 58 times. They sold a total of 969,114 shares worth more than $33,269,224.75. The most recent insider tranaction occured on March, 17th when insider Catriona Yale sold 10,000 shares worth more than $447,600.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 3/17/2025.

Patrick Lamy Insider Trading History at Akero Therapeutics

See Full Table

Patrick Lamy Buying and Selling Activity at Akero Therapeutics

This chart shows Patrick Lamy's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$333ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $42.33
Low: $41.84
High: $45.18

50 Day Range

MA: $44.85
Low: $22.31
High: $57.56

2 Week Range

Now: $42.33
Low: $17.86
High: $58.40

Volume

258,191 shs

Average Volume

805,683 shs

Market Capitalization

$3.37 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A